Browse By

Kane Biotech Announces 2023 Achievements

Kane aims to disrupt global wound care hydrogel market with its first FDA cleared medical device and announces new partnerships and licensing agreements  Kane Biotech has announced several partnerships and licensing agreements in both wound care and animal health in 2023. The recent announcement of

Kane Biotech in the News 2023

In 2023, Kane Biotech has been featured in several news media articles, including  BNN Bloomberg and Benzinga, as well as a podcast with Kane is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. With a

Kane Biotech: A Year in Review 2022

As 2022 draws to a close, Kane Biotech reflects upon its achievements in the last year. Kane refers to itself as THE Biofilm Company, with over 80 patents and patents pending. Kane focused its efforts in 2022 on further developing its wound care product pipeline

T.I.M.E. Assessment to Treat Wounds Impacted by Biofilms

As researchers continue to study the impacts of biofilms on wounds, individuals living with chronic wounds often experience a negative impact on their overall physical and mental health, especially for those whose wounds continue for months or even years. Chronic wound patients commonly report concerns

Kane Biotech Announces Achievements in October 2022

Kane Biotech experienced significant achievements in October 2022, for both their coactiv+™ and their DispersinB® technologies. For over 20 years, Kane has been developing new technologies and innovations, leading to 80 patents and patents pending in biotechnology focusing primarily on biofilm. Kane Biotech Announces 510(k)

Antibiotic Resistance & Biofilms: The Next Pandemic

Antimicrobial resistance (AR) occurs when bacteria are exposed to levels of antibiotics that fail to kill the bacteria. For example, when an antibiotic that was able to treat an infection previously is no longer able to effectively kill bacteria, and results in an ongoing or

Biofilm: Protector of Bacteria & Fungi

The National Institute of Health reports that 80% of all known human infections are associated with biofilms. Biofilms are a serious and urgent clinical and financial burden to health care systems and patients, costing industry, cities, and hospitals over $500 billion each year. What are